NewslettersImmune Regulation NewsTakeda Announces Positive Topline Results from Pivotal Phase III Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)By lbeveridge - July 25, 20220168Takeda announced that ADVANCE-1, a randomized, placebo-controlled, double-blind Phase III clinical trial evaluating HYQVIA® for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropath, met its primary endpoint.[Takeda]Press Release